Option chain shows key data for Regen BioPharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Regen BioPharma.

Regen BioPharma (OTC:RGBPP) Stock, Option Chain

Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AGHC

ANGI

ASCOT RESOURCES LTD by Ascot Resources Ltd.

AOTVF

ASDZF

ARTEMIS THERAPEUTICS INC by Artemis Therapeutics, Inc.

ATMS

BIG BLOCKCHAIN INTELGNCE by Big Blockchain Intelligence Group Inc.

BBKCF

BFALL

BSPK

BYZN

CCSB

CELLCUBE ENERGY STORAGE by Cellcube Energy Storage Sys Inc.

CECBF

CEFC

CHDGF

China TechFaith Wirelessmmunication Technology

CNTF

COFOL

CTIB

CYIG

DFMTF

DMNKF

DPLS

EOPT

ESTR

FLES

FRLI

FTPLF

FTXP

FUAPF

FUTL

GAXY

GBHPF

HQGE

HSKA

HTGM

INQD

INSYQ

IPNFF

IRIX

ISWH

IVITF

JINFF

MCIG

MRSN

MXROF

MYOV

NABIF

NOHO

NRBT

OPMZ

OXBDF

OZSC

PDLI

PDNLA

PHVAF

PTVL

QMC QUANTUM MINERALS CORP by QMC Quantum Minerals Corp.

QMCQF

REGEN BIOPHARMA INC PFD by Regen Biopharma, Inc.

RGBPP

RTNB

RTTR

SAMMF

SHGXY

SNAVF

SPLIF

STKXF

SYHBF

SZBI

TBEV

TRIB

TTNP

TUSK

TWOH

VIDA

VLRX

VRME

VVCIF

VYEY

WMLLF

FRFFF

UNJCF

GRDZF

DGTLF

BRTZF

SDXEF

SDPI

POROF

BFARF

SCYYF

NVLPF

GEEPF

GAYGF

MMIRF

GTARF

Stocks That Hit 52-Week Lows On Friday

REGEN BIOPHARMA PFD A by Regen Biopharma, Inc.

Regen BioPharma Inc

Small Cap

Press Releases

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on March 7, 2024

Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time

Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™

RGBAD

RGBP

RGBPD

Regen BioPharma

Comments

Regen BioPharma

Regen BioPharma (RGBPP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga